Immunobiology of acute graft-versus-host disease

Blood Reviews

Volumn 17, Issue 4, 2003, Pages 187-194

  Reddy, Pavan ^a   Ferrara, James L M ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

APC; CTL; Cytokines; NK cells; Th1; Th2

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOTHERAPY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOBIOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTESTINE MUCOSA; IRRADIATION; MONONUCLEAR PHAGOCYTE; NATURAL KILLER CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE INJURY;

EID: 0242291765     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(03)00009-2     Document Type: Review

References (119)

1. Ferrara JLM, Deeg HJ. Graft versus host disease. N Engl J Med 1991; 324:667-674.
2. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001; 29: 259-277.
3. Hill G, Ferrara J. The primacy of the gastrointestinal tract as a targe organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
4. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360-2367.
5. Chang RJ, Lee SH. Effects of interferon-γ and tumor necrosis factor-α on the expression of an 1a antigen on a murine macrophage cell line. J Immunol 1986; 137: 2853-2856.
6. Pober JS, Orosz CG, Rose ML. Can graft endothelial cells initiate a host anit-graft immune response. Transplantation 1996; 61: 343-349.
7. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-305.
8. Cliff RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: randomized trial of two irradiation regimens. Blood 1990; 76: 1867-1871.
9. Ringden O. Viral infections and graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-vs-Host Disease. New York: Marcel Dekker; 1990: 467.
10. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C, Kolesnick R. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001; 293: 293-297.
11. Teshima T, Ferrara JL. Understanding the alloresponse: new approaches to graft-versus-host disease prevention. Semin Hematol 2002; 39: 15-22.
12. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR, Ferrara JL. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575-581.
13. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
14. Ordemann R. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intesnifies acute graft-versus-host disease. JCI 2002.
15. Sallusto F, Lanzavecchia A. The instructive role of dendritic cells on T-cell responses. Arthritis Res 2002; 4(Suppl 3): S127-132.
16. Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML. The immunological synapse. Annu Rev Immunol 2001; 19: 375-396.
17. Dustin ML. Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol 2001; 21: 258-263.
18. Murphy WJ, Blazar BR. New strategies for preventing graft-versus-host disease. Curr Opin Immunol 1999; 11: 509-515.
19. Ferrara J, Antin J. Pathophysiology of human GVHD. In: Forman S, Blume K, Thomas E, eds. Hematopoietic Cell Transplantation. Blackwell Science; 1999. p. 305-315.
20. Korngold R, Sprent J. T cell subsets in graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-vs-Host Disease: Immunology, Pathophysiology, and Treatment. New York: Marcel Dekker; 1990: 31-50.
21. Ho IC, Glimcher LH. Transcription: tantalizing times for T cells. Cell 2002; 109(Suppl): S109-S120.
22. Tseng SY, Dustin ML. T-cell activation: a multidimensional signaling network. Curr Opin Cell Biol 2002; 14: 575-580.
23. Hill G, Krenger W, Ferrara J. Cytokine dysregulation in acute graft-versus-host disease. Hematology 1998; 2: 423.
24. Via CS, Finkelman FD. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int Immunol 1993; 5: 565-572.
25. Jadus MR, Peck AB. Lethal murine graft-versus-host disease in the absence of detectable cytotoxic T lymphocytes. Transplantation 1983; 36: 281-289.
26. Theobald M, Nierle T, Bunies D, Arnold R, Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 1992; 327: 1613-1617.
27. Ferrara JLM, Marion A, McIntyre JF, Murphy GF, Burakoff SJ. Amelioration of acute graft-versus-host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody. J Immunol 1986; 137: 1874-1877.
28. Belanger C, Esperou-Bourdeau H, Bordigoni P, Jouet JP, Souillet G, Milpied N, Troussard X, Kuentz M, Herve P, Reiffers J, Demeocq F, Dauriac C, Blaise D, Michallet M, Friere D, Freycon F, Gratecos N, Rio B, Leblond V, Ifrah N, Attal M, Bergerat JP, Vilmer E, Pico J, Raffoux C, Caudrelier P, Gluckman E. Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transpl 1993; 11: 293-297.
29. Anasetti C, Martin PM, Hansen JA, Appelbaum FR, Beatty PG, Doney K, Harkonen S, Jackson A, Reichert T, Stewart P, Storb R, Sullivan K, Donnall Thomas E, Warner N, Witherspoon RP. A phase I-II study evaluating the murine anti-IL-2 receptor antibody2A3 for treatment of acute graft-versus-host disease. Transplantation 1990; 50: 49-54.
30. Li XC, Demirci G, Ferrari-Lacraz S, Groves C, Coyle A, Malek TR, Strom TB. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med 2001; 7: 114-118.
31. Kumaki S, Minegishi M, Fujie H, Sasahara Y, Ohashi Y, Tsuchiya S, Konno T. Prolonged secretion of IL-15 in patients with severe forms of acute graft-versus-host disease after allogeneic bone marrow transplantation in children. Int J Hematol 1998; 67: 307-312.
32. Hill GR, Crawford JM, Cooke KJ, Brinson YS, Pan L, Ferrara JLM. Total body irradiation and acute graft versus host disease. The role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-3213.
33. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
34. Velardi A, Varese P, Terenzi A, Dembech C, Albi N, Grossi CE, Moretta L, Martelli MF, Grignani F, Mingari MC. Lymphokine production by T-cell clones after human bone marrow transplantation. Blood 1989; 74: 1665-1672.
35. Niederwieser D, Herold M, Woloszczuk W, Aulitsky W, Meister B, Tilg H, Gastl G, Bowden R, Huber C. Endogenous IFN-γ during human bone marrow transplantation. Transplantation 1990; 50: 620-625.
36. Mowat A. Antibodies to IFN-γ prevent immunological mediated intestinal damage in murine graft-versus-host reactions. Immunology 1989; 68: 18-24.
37. Dickinson AM, Sviland L, Dunn J, Carey P, Proctor SJ. Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro skin explant model. Bone Marrow Transpl 1991; 7: 209-216.
38. Klimpel GR, Annable CR, Cleveland MG, Jerrels TR, Patterson JC. Immunosuppression and lymphoid hypoplasia associated with chronic graft-versus-host disease is dependent upon IFN-g production. J Immunol 1990; 144: 84-93.
39. Wall DA, Sheehan KC. The role of tumor necrosis factor-α and interferon γ in graft-versus-host disease and related immunodeficiency. Transplantation 1994; 57: 273-279.
40. Brochu S, Rioux-Masse B, Roy J, Roy DC, Perreault C. Massive activation-induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versus-host disease. Blood 1999; 94: 390-400.
41. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor α during graft-versus-host disease. J Exp Med 1992; 175: 405-413.
42. Reddy P, Teshima T, Kukuruga M, Ordemann R, Liu C, Lowler K, Ferrara JL. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001; 194: 1433-1440.
43. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon γ is required for activation-induced death of T lymphocytes. J Exp Med 2002; 196: 999-1005.
44. Ferrara JLM. Paradigm shift for graft-versus-host disease. Bone Marrow Transpl 1994; 14: 183-184.
45. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
46. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma 2000; 38: 221-234.
47. Brok HPM, Heidt PJ, van der Meide PH, Zurcher C, Vossen JM. Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 1993; 151: 6451-6459.
48. Sykes M, Romick ML, Sachs DH. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA 1990; 87: 5633-5637.
49. Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibits murine graft-versus-host disease. Blood 1995; 86: 2429-2438.
50. Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA, Vallera DA, Kopf M, Young H, Longo DL, Blazar BR. Differential effects of the absence of interferon-γ and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 1998; 102: 1742-1748.
51. Ellison CA, Fischer JMM, HayGlass KT, Gartner GJ. Murine graft-versus-host disease in a FI-hybrid model using IFN-γ gene knockout donors. The Journal of Immunolgy 1998; 161: 631-640.
52. Welniak LA, Blazar BR, Wiltrout RH, Anver MR, Murphy WJ. Role of interleukin-12 in acute graft-versus-host disease (I). Transpl Proc 2001; 33: 1752-1753.
53. Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995; 85: 842-851.
54. Ushiyama C, Hirano T, Miyajima H, Okumura K, Ovary Z, Hashimoto H. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. J Immunol 1995; 154: 2687-2696.
55. Liu J, Anderson BE, Robert ME, McNiff JM, Emerson SG, Shlomchik WD, Shlomchik MJ. Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease. Blood 2001; 98: 3367-3375.
56. Reddy P, Teshima T, Hildebrandt G, Williams DL, Liu C, Cooke KR, Ferrara JL. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood 2002.
57. Hill GR, Cooke KR, Teshima T, Crawford JM, Keith JC, Brinson YS, Bungard D, Ferrara JLM. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 1998; 102: 115-123.
58. Zeng D, Lewis D, Dejbakhsh-Jones S, Lan F, Garcia-Ojeda M, Sibley R, Strober S. Bone marrow NK1.1 - and NK1.1 + T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999; 189: 1073-1081.
59. Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 2000; 105: 1289-1298.
60. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med 2001; 344: 655-664.
61. Wekerle T, Kurtz J, Ito H, Ronquillo JV, Dong V, Zhao G, Shaffer J, Sayegh MH, Sykes M. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464-469.
62. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001; 14: 417-424.
63. Li XC, Strom TB, Turka LA, Wells AD. T cell death and transplantation tolerance. Immunity 2001; 14: 407-416.
64. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001; 166: 973-981.
65. Van Parijs L, Ibraghimov A, Abbas AK. The roles of costimulation and Fas in T-cell apoptosis and peripheral tolerance. Immunity 1996; 4: 321-328.
66. Sykes M, Abraham VS. The mechanism of IL-2-mediated protection against GVHD in mice. II. Protection occurs independently of NK/ LAK cells. Transplantation 1992; 53: 1063-1070.
67. Yang YG, Sykes M. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD. Leuk Lymphoma 1999; 33: 409-420.
68. Wekerle T, Kurtz J, Sayegh M, Ito H, Wells A, Bensinger S, Shaffer J, Turka L, Sykes M. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol 2001; 166: 2311-2316.
69. Drobyski WR, Komorowski R, Logan B, Gendelman M. Role of the passive apoptotic pathway in graft-versus-host disease. J Immunol 2002; 169: 1626-1633.
70. Drobyski WR, Gendelman M. Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene. Leuk Lymphoma 2002; 43: 2011-2016.
71. Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 2002; 99: 3083-3088.
72. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399.
73. Johnson BD, Konkol MC, Truitt RL. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transpl 2002; 8: 525-535.
74. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196: 401-406.
75. Taylor PA, Friedman TM, Korngold R, Noelle RJ, Blazar BR. Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. Blood 2002; 99: 4601-4609.
76. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-3499.
77. Taylor PA, Friedman TM, Korngold R, Noelle RJ, Blazar B. Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. Blood 2002; 99: 4601-4609.
78. Tamada K, Tamura H, Flies D, Fu YX, Celis E, Pease LR, Blazar BR, Chen L. Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest 2002; 109: 549-557.
79. Murai M, Yoneyama H, Harada A, Yi Z, Vestergaard C, Guo B, Suzuki K, Asakura H, Matsushima K. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest 1999; 104: 49-57.
80. Serody JS, Cook DN, Kirby SL, Reap E, Shea TC, Frelinger JA. Murine T lymphocytes incapable of producing macrophage inhibitory protein-I are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier. Blood 1999; 93: 43-50.
81. Serody JS, Burkett SE, Panoskaltsis-Mortari A, Ng-Cashin J, McMahon E, Matsushima GK, Lira SA, Cook DN, Blazar BR. T-lymphocyte production of macrophage inflammatory protein-1α is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 2000; 96: 2973-2980.
82. New JY, Li B, Koh WP, Ng HK, Tan SY, Yap EH, Chan SH, Hu HZ. T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transpl 2002; 29: 979-986.
83. Choi EY, Christianson GJ, Yoshimura Y, Jung N, Sproule TJ, Malarkannan S, Joyce S, Roopenian DC. Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease. Blood 2002; 100: 4259-4264.
84. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-1947.
85. Murphy WJ, Koh CY, Raziuddin A, Bennett M, Longo DL. Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies. Immunol Rev 2001; 181: 279-289.
86. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
87. Asai O, Longo DL, Tian Z, Hornung RL, Taub DD, Ruscetti FW. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998; 101: 1835-1842.
88. Wang JW, Howson JM, Ghansah T, Desponts C, Ninos JM, May SL, Nguyen KH, Toyama-Sorimachi N, Kerr WG. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 2002; 295: 2094-2097.
89. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530.
90. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20: 323-370.
91. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996; 183: 2645-2656.
92. Graubert TA, Russell JH, Ley T. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood 1996; 87: 1232-1237.
93. Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/ granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 1997; 100: 904-911.
94. van den Brink MR, Burakoff SJ. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2002; 2: 273-281.
95. Ueno Y, Ishii M, Yahagi K, Mano Y, Kisara N, Nakamura N, Shimosegawa T, Toyota T, Nagata S. Fas-mediated cholangiopathy in the murine model of graft versus host disease. Hepatology 2000; 31: 966-974.
96. Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K. Differential effects of anti-Fas ligand and anti-tumor necrosis factor-α antibodies on acute graft-versus-host disease pathologies. Blood 1998; 91: 4051-4055.
97. Kanda Y, Tanaka Y, Shirakawa K, Yatomi T, Nakamura N, Kami M, Saito T, Izutsu K, Asai T, Yuji K, Ogawa S, Honda H, Mitani K, Chiba S, Yazaki Y, Hirai H. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transpl 1998; 22: 751-754.
98. Braun YM, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996; 183: 657-661.
99. Martin PJ, Akatsuka Y, Hahne M, Sale G. Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection. Blood 1998; 92: 2177-2181.
100. Jiang Z, Podack E, Levy RB. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis. Blood 2001; 98: 390-397.
101. Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon JJ, Van Den Brink MR. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 2002; 8: 1433-1437.
102. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-680.
103. Nestel F, Kichian K, You-Ten K, Desbarats J, Price K, Lapp WS. The role of endotoxin in the pathogenesis of acute graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs-Host Disease, 2nd ed. New York: Marcel Dekker; 1996.
104. Cooke K, Gerbitz A, Hill G, Crawford J, Teshima T, Ferrara JLM. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 7: 1581-1589.
105. Herve P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P, Plouvier E, Stephan JL, Bourdeau H, Holler E, Lioure B, Roche C, Vilmer E, Demeocq F, Kuentz M, Cahn YJ. Phase I-II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 81: 1993-1999.
106. Gilliam AC, Whitaker-Menezes D, Korngold R, Murphy GF. Apoptosis is a major form of cell injury in experimental acute graft-versus-host disease in skin and mucosa. J Invest Dermatol 1996; 106: 927.
107. Cooke K, Hill G, Gerbitz A, Kobzik L, Martin T, Crawford J, Brewer J, Ferrara J. TNFα neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 2000; 70: 272-279.
108. Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, Greenberg AS, Willis LM, Murphy GF, Crawford JM, Van Den Brink MR. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 2002.
109. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 1988; 141: 2629.
110. Abhyankar S, Gilliland DG, Ferrara JLM. Interleukin I is a critical effector molecule during cytokine dysregulation in graft-versus-host disease to minor histocompatibility antigens. Transplantation 1993; 56: 1518-1523.
111. Atkinson K, Matias C, Guiffre A, Seymour R, Cooley M, Blggs J, Munro V, Gillis S. In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 1991; 77: 1376-1382.
112. Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, Crawford JM, Ferrara JL. Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft versus leukemia. J Clin Invest 1999; 104: 459-467.
113. McCarthy PL, Abhyankar S, Neben S, Newman G, Sieff C, Thompson RC, Burakoff SJ, Ferrara JLM. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915-1918.
114. Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, Alyea E, McGarigle C, Blazar BR, Sonis S, Soiffer RJ, Ferrara JL. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002; 100: 3479-3482.
115. Langrehr JM, Murase N, Markus PM, Cai X, Neuhaus P, Schraut W, Simmons RL, Hoffmann RA. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J Clin Invest 1992; 90: 679-683.
116. Weiss G, Schwaighofer H, Herold M. Nitric oxide formation as predictive parameter for acute graft-versus-host disease after human allogeneic bone marrow transplantation. Transplantation 1995; 60: 1239-1244.
117. Falzarano G, Krenger W, Snyder KM, Delmonte J, Karandikar M, Ferrara JLM. Suppression of B cell proliferation to lipopolysaccharide is mediated through induction of the nitric oxide pathway by tumor necrosis factor-a in mice with acute graft-versus-host disease. Blood 1996; 87: 2853-2860.
118. Krenger W, Falzarano G, Delmonte J, Snyder KM, Byon JCH, Ferrara JLM. Interferon-γ suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood 1996; 88: 1113-1121.
119. Nestel FP, Greene RN, Kichian K, Ponka P, Lapp WS. Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: release of intracellular iron and nitric oxide-mediated cytostasis. Blood 2000; 96: 1836-1843.